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L-glutamic acid, y-(p-hydroxyanilide), is a naturally 
occurring metabolic inhibitor found in mushrooms and 
shown to be active against B-16 melanoma in vivo. We 
have prepared and evaluated 2 analogs, the 3,4- and 2,5-
dihyd.roxy derivatives, since these might represent more 
immediate precursors to the putative biologically active 
quinone. Both dihydroxy derivatives were more toxic 
than the parent phenol. The 2,5-dihydroxy derivative 
was significantly more cytotoxic with a 5-fold decrease 
in IC50 for both human and B-16 melanoma cells in vitro. 
In the presence of mushroom tyrosinase, both deriva-
tives were potent inhibitors of isolated DNA polymerase 
with essentially complete inhibition occurring at concen-
trations of 10-• M. The 3,4-dihydroxy derivative exerted 
inhioitory effects primarily upon thymidine incorpora-
tion into melanoma cells in vitro while the 2,5-dihyd.roxy 
derivative also inhibited uridine and leucine incorpora-
tion. There was no significant antitumor activity ob-
served in the B-16 system, a fact which might be attrib-
uted to the increased toxicity of the compounds. 
L-Glutamic acid y-(p-hydroxyanilide) is a naturally occurring 
phenol isolated from the gills of the common mushroom Agar-
icus bisporus which acts as a growth regulator [1]. This phenol 
is converted to a quinone by the action ofthe enzyme tyrosinase 
which is also present in the mushroom. The natural role of the 
quinone metabolite is believed to be the induction and main-
tenance of spore dormancy, a "cryptobiotic" state in which 
energy production and macromolecule biosynthesis cease. The 
phenol has been used to inhibit the growth of B-16 melanoma 
in the mouse, presumably because conversion to the quinone is 
mediated by large amounts of the enzyme tyrosinase [2,3). The 
quinone has .been shown to be a potent inhibitor of mammalian 
DNA polymerase as well as other sulfhydryl dependent en-
zymes. 
We have recently described the synthesis of 9 structural 
analogs of the phenol, L-glutamic acid (y-p-hydroxyanilide) 
[ 4], and now report the effects of the dihydroxy derivatives 
upon the growth of B-16 melanoma. These dihydroxy deriva-
tives may be the putative quinol versions of the metabolically 
active quinone. Although it was originally proposed that the 
biologically active quinone was the ortho-quinone (Fig 1; 3), 
recent evidence has supported a different structural assignment 
(Fig 1; 4) [5]. Since this trihydroxy derivative might be obtain-
able, in principle, from either dihydroxy precursor by the action 
of the oxidative enzyme tyrosinase, we undertook to evaluate 
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the antitumor effects of both the 3,4- and 2,5-dihydroxyanilides 
upon the tyrosinase positive B-16 murine melanoma and human. 
melanoma cells (Fig 1, 2). 
MATERIALS AND METHODS 
Drugs 
All drugs used in this study were reagent grade and obtained fro~ 
Sigma Chemical Company, St. Louis, MO. Radiolabeled [methylJ H) 
thymidine, [methyl-3H]thymidine triphosphate, [5-3H]uridine, and L 
[ 4,5-3H]leucine were from the New England Nuclear Company, Boston, 
MA. All other materials were reagent grade and used without further 
purification. The details for the synthesis of the analogs have been 
reported [4]. Briefly, the corresponding dirnethoxyaniline was con. 
densed with the commercially available protected forms of L-glutamic 
acid in the presence of dicyclohexylcarbodiimide and 1-hydroxybenzo. 
triazole. The adduct was then treated with boron tribromide which 
simultaneously removed the carbobenzyloxy, benzyl, and methyl pro. 
tecting groups. The desired products were obtained in 60 to 70% overall 
yield. The synthesis of the 3,4-dihydroxy derivative has previously been 
reported by a different route [6]. All ultraviolet and visible spectra were 
recorded on a Cary Model 11 and Model 15 spectrophotometer. The 
spectra were recorded after incubating the respective dihydroxy deriv. 
ative in phosphate buffer 0.001 M, pH 6.8 containing mushroom tyro. 
sinase (0.5 mg/rnl) (Sigma Company, St. Louis, MO) for 30 min at 
27°C. 
In Vivo Antitumor A ssays 
(C57BL/6 X DBA/2) F 1 male mice 6 to 8 weeks of age were obtained 
from the Jackson Laboratory, Bar Harbor, Maine. Assay procedures 
were identical to that of standard National Cancer Institute protocols 
and have been reported in detail [7]. 
In Vitro Assays 
The B-16 cells were started from a deeply pigmented tumor obtained 
from Jackson Laboratory, Bar Harbor, Maine and maintained in mono-
layers in McCoys' 5A medium with 10% fetal calf serum and antibiotics. 
The origin and maintenance of the human melanoma cells has been 
described [8]. The techniques for radiolabeled precursor incorporation 
studies have also been described [9]. 5 X 105 cells were exposed to 1 
~tCi/ml of labeled precursor and the appropriate concentration of drug 
for 60 min. The media was removed and the cells precipitated with 10% 
trichloroacetic acid. Following digestion with 1.0 N KOH, an aliquot of 
the digest was added to scintillation vials containing Aquasol (New 
England Nuclear Company) and counted in a Beclunan LS335 scintil-
lation counter. All determinations were in triplicate with values ex-
pressed as the mean ± SEM for 3 to 5 experiments and compared to 
nontreated controls. 
DNA Polymerase Inhibition 
DNA polymerase a from calf thymus was obtained from Miles 
Laboratories, Inc., Elkhart, Indiana. The final assay mixture consisted 
of 50 mM KCl, 40 mM potassium phosphate, 2 mM MgCh, 80 ~tM dA TP, 
dCTP, dGTP, 7 ~tM dTTP, 50 p.g calf thymus DNA and 0.2 to 0.8 ~tCi 
of [aH] TTP specific activity 53 Ci/mmole. The incubations were 
conducted for 30 min at 37°C resulting in incorporation of 2-3 pmoles 
of TTP. The reactions were terminated by cooling to 0°C and adding 
0.1 ml of 0.1 M sodium pyrophosphate containing heat inactivated 
sperm DNA and 5 ml of 5% trichloroacetic acid. The filtrates were 
collected on a Whatman GF !C filter, washed with trichloroacetic acid, 
dried, and digested with 0.5 rnl Protosol (New England Nuclear, Boston, 
MA). Following addition of scintillation fluid, the samples were counted 
in a scintillation counter. 
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RESULTS 
As reported previously, 3,4-DHA yielded a pink colored so-
lution when exposed to mushroom tyrosinase corresponding to 
the generation of an absorption maximum at 490 nm. 2,5-DHA 
under the same conditions did not generate a discrete maximum 
but rather diffuse absorption. 
Table I summarizes the in vitro and in vivo toxicity data for 
the dihydroxy derivatives 3,4-DHA and 2,5-DHA. Examination 
of the effects of these drugs upon the growth of B-16 and human 
melanoma cells reveals that 3,4-DHA is somewhat less potent 
than the p~ent phenol while 2,5-DHA is more cytotoxic, es-
pecially agamst the human melanoma cell. Both dihydroxy 
derivatives, however, were more toxic in vivo as reflected in the 
LD50 doses which were four times lower than that of the parent 
phenol. 
Table II summarizes the results of our studies upon the 
pattern of inhibition of thymidine, uridine, and leucine incor-
poration by B-16 melanoma cells in vitro. Once again, the 2,5-
dihydroxy derivative is the more potent with complete inhibi-
tion of thymidine incorporation at concentrations of 0.1 mM. 
Furthermore, there is no selectivity observed with this deriva-
tive with similar dose responses for both uridine and leucine 
incorporation. 3,4-DHA is less effective in tenns of overall 
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FIG 1. Structural formulas for 3,4-DHA (1) and 2,5-DHA (2). The 
quinone forms represented by 3 and 4 ru·e alternate putative structures 
for the naturally occurring inhibitory quinone. 
TABLE I. Cytotoxicity of hydroxyanilides for human and B-16 
melanoma cells and acute toxicity in mice 
Drug 
MHA 
3,4DHA 
2,5DHA 
IC50 (mM)" 
Human melanoma 
0.05 
0.090 
0.022 
B-16 melanoma 
.10 
0.27 
0.050 
LD50 (mg/ kg)• 
BDF, mice 
500 
125 
125 
a Concentration that caused a 50% reduction in growth of exponen-
tially growing cells following 48 hr of exposure. The values for the 
MHA and 3,4 DHA against B-16 melanoma are included for reference 
[4]. 
b Single dose toxicity study, 10 mice/group and observed for 30 days. 
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inhibition compared to uridine or leucine incorporation. The 
values for the parent MHA are included for reference. 
Figure 2 shows the effects of tyrosinase-generated products 
of 3,4-DHA upon isolated DNA polymerase [10]. Tyrosinase 
(10 {!g/ml) by itself did not affect the efficiency of the DNA 
polymerase. 3,4-DHA alone did not inhibit DNA polymerase 
but with the addition of tyrosinase, a prompt and marked 
inhibition ?ccured. This inhibition was complete at 3,4-DHA 
concentratiOns greater than 10- 5 M. A similar dose response 
TABLE II. Effects of hydroxyanilides upon thymidine, uridine, and 
leucine incorporation in B-16 melanoma 
Concentration Thymidine Uridine Leucine" (mM) % Inhibition 
3,4 DHA 0.1 0 0 0 
0.5 10 10 4 
1.0 36 20 8 
2.0 75 35 27 
2,5 DHA 0.1 68 76 55 
0.5 90 95 79 
1.0 92 95 87 
2.0 96 95 88 
MHA 0.1 10 0 0 
0.5 52 8 0 
1.0 64 29 0 
2.0 73 32 8 
"Exponentially growing cells were exposed to · drug at 0.1, 0.5, 1.0, 
and 2.0 mM concentrations. Values represent the % inhibition for 
triplicate sample. The average standru·d error was 10%. Control cells 
incorporated the following values (cpm/ 105 cells) Thymidine: 10,440; 
uridine: 8,927; leucine: 3,100. 
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FIG 2. Dose response curves for the inhibition of DNA polymerase 
by 2,5-DHA (0 ) and 3,4-DHA (e) in the presence of tyrosinase (10 p.g/ 
tnl) . Neither tyrosinase nor quinol alone inhibited the polymerase. 
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curve was observed when 2,5-DHA was studied. In the absence 
of tyrosinase, no inhibitory effect upon the enzyme could be 
observed. 
When tested against the B-16 melanoma in vivo by daily 
intraperitoneal injection at doses ranging from 10 to 75 mg/kg, 
there was no significant prolongation of survival observed with 
either 3,4-DHA or 2,5-DHA. At higher doses, significant toxicity 
was observed. 
DISCUSSION 
Melanoma cells possess a unique enzymatic apparatus for the 
conversion of levodopa to the pigment melanin. It has been 
suggested that it may be possible to take advantage of the very 
high intracellular oxidative potential associated with the mel-
anin pathway to design chemotherapeutic agents for melanoma 
[8-10]. 
Since the phenol L-glutamic acid y-4-hydroxyanilide (MHA) 
was reported [3] to be inhibitory to the growth of B-16 mela-
noma, it seemed reasonable to prepare more readily oxidizable 
analogs in order to enhance activity. Our studies support the 
concept that cytotoxicity is, indeed, related to ease of oxidation, 
since each of the dihydroxy analogs of MHA is more toxic than 
the parent phenol when administered in vivo. The 2,5-dihy-
droxy derivative particularly is also more cytotoxic in vitro, 
suggesting that para positioning of hydroxy groups leads to an 
increased effect. 
As reported earlier (3], the oxidation product of 3,4-DHA is 
a potent inhibitor of isolated DNA polymerase. Isomeric sub-
stitution of hydroxy groups in the 2,5-dihydroxy derivatives 
results in retention of the ability to inhibit DNA polymerase in 
the presence of tyrosinase. We have previously shown that 6-
hydroxydopa, an analog of levodopa, differs significantly from 
the latter in the pattern of macromolecular synthesis inhibition 
[ll]. A similar phenomenon is observed h ere, with the para 
derivative ·being less selective than the ortho. 
Several mechanisms of cytotoxicity have been proposed for 
catechols, including inhibition of DNA polymerase by quinone 
metabolites and the intracellular generation of free radicals [ll, 
12]. It may be that, depending on which isomeric arrangement 
of hydroxy groups is present, one of these mechanisms is 
preferred. 
At the present time, we do not have a definitive explanation 
for the marked host toxicity of 3,4-DHA and 2,5-DHA. One 
possibility that might be considered is cleavage of the y-gluta-
myl amide bond, which would release 3,4-dihydroxyaniline and 
Vol. 74, No.2 
2,5-dihydroxyaniline respectively. 3,4-Dihydroxyaniline is 
chemically a very unstable species, and data regarding its 
toxicity are unavailable in the literature. On the other hand, 
Torigoe [3] has reported the single-dose LD50 of 2,5-dihydrox-
yaniline in rats to be 30 mg/ kg, and it seems very likely that 
the 3,4-dihydroxy compound would exhibit similar toxic prop-
erties. Perhaps, further chemical modification might result in 
increased stability of the amide bond and reduce systemic 
toxicity. 
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Correction 
In the October issue in the article "Ro 20-1724: An Agent that Significantly Improves Psoriatic Lesions 
in Double-Blind Clinical Trials" by Stawiski et a! (73:261-263) Table II (which appeared on page 262) 
was misprinted. The correct version of the table appears here. 
TABLE II. Clinical effects by drug concentration of Ro 20- 1724 on 
psoriasis" 
Number of test sites at each 
Concentrations of concentration 
Ro 20- 1724 
1% .5% .25% P lacebo 
Response 
2 11 11 8 0 
l 7 7 10 4 
0 0 0 0 14 
" Each of the nine patients tested in duplicate sites with the prepa-
rations above (see text). A possible dose response effect may be present 
at the 0.25% concentration. Response was graded as fo llows: no im-
provement = 0, minimal improvement = l, and moderate or better 
improvement = 2. 
